Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by SizzlinSteakson Dec 20, 2017 8:10am

180 Views

Post# 27193727

RE:Chart Stuff for those that want it & if you don't, BLOCK ME

I am heavily invested here but if you want another amazing cannabis play check out VP. They have the lowest
market cap (14 million) and lowest shares outstanding (28 million) of all cannibas plays and the chart looks
ready for a break out. Additionally they are getting very close to news on a couple of fronts 1. finalizing their new processing facility in Bellingham, Washington and 2. receiving Health Canada approval. This will both be
significant catalyst in driving their valuation and bringing it up to similar valuations of other producing plays.
Great opportunity IMO. Certainly worth looking at.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal